Several research groups around the world reported on the use of the drug misoprostol in the medical management of miscarriage, abortion and induction of labour. This review examines the evolution of interest in this drug, with special emphasis on its role in induction of labour.
PIP: The induction of labor by prostaglandin agents has been a central research focus for the past 30 years, but their use has been compromised by the high incidence of gastrointestinal side effects. During the late 1970s, the research focus shifted to sequential vaginal administration of different prostaglandin analogues. Currently, the pharmaceutical industry is especially interested in the role of misoprostol in inducing uterine contractibility. Required first, however, is the determination of the correct dosage and frequency that will induce effective uterine contractions without producing uterine hyperstimulation and adverse effects on the fetal heart rate. Because of its thermostability, efficacy, and low cost, the therapeutic use of misoprostol is expected to increase throughout the world in the years ahead.